SCHEMBL487416

SCHEMBL487416

CC(C)(C)OC(=O)C[C@H](N)[C@@H](O)COc1c(F)c(F)cc(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
CYP2D6 P10635 1/20 0.34
DPP4 P27487 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
CASP3 P42574 4/20 0.33
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CASP7 P55210 1/20 0.31
CASP6 P55212 1/20 0.31
CASP8 Q14790 1/20 0.31
CTSV O60911 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3209608 1.00 MAPT (0.35) MAPTKDM4EALDH1A1HTTCYP2D6
SCHEMBL473148 1.00 MAPT (0.35) MAPTKDM4EALDH1A1HTTCYP2D6
SCHEMBL79263 1.00 MAPT (0.35) MAPTKDM4EALDH1A1HTTCYP2D6
SCHEMBL77864 0.89 CTSK (0.37) CYP2D6MTNR1AMTNR1BALOX5APFEN1
SCHEMBL20981028 0.88 MAPT (0.34) MAPTKDM4EALDH1A1HTTDPP4
SCHEMBL78318 0.88 MAPT (0.36) MAPTCYP2D6DPP4MTNR1AMTNR1B
SCHEMBL8337923 0.85 MAPT (0.33) MAPTKDM4EALDH1A1HTT
SCHEMBL20827204 0.83 MAPT (0.36) MAPTKDM4EALDH1A1HTTCYP2D6
SCHEMBL20826999 0.82 MAPT (0.40) MAPTKDM4EALDH1A1HTTCASP3
SCHEMBL23268871 0.82 CYP2D6 (0.36) MAPTKDM4EALDH1A1HTTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362043-B2 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-29 US disclosed
EP-1833794-B1 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS VERTEX PHARMA (US) 2012-02-01 EP disclosed
US-20060160862-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160862-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP3 MAPT 2777/4885KDM4E 1305/4885ALDH1A1 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.